Beckermann, K., Campbell, M. T., Haas, N. B., Ornstein, M. C., Gao, X., Mao, S. S., … Shah, N. J. (2023). Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Beckermann, Katy, Matthew T. Campbell, Naomi B. Haas, Moshe Chaim Ornstein, Xin Gao, Shifeng S. Mao, Hans J. Hammers, et al. “Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Beckermann K, Campbell MT, Haas NB, Ornstein MC, Gao X, Mao SS, et al. Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC). In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Beckermann, Katy, et al. “Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Beckermann K, Campbell MT, Haas NB, Ornstein MC, Gao X, Mao SS, Hammers HJ, George S, Nelson AA, Gourdin TS, Keshava-Prasad H, Hussain A, Hoimes CJ, Yan H, Esquibel V, McIntyre G, Geller RB, Voss MH, Rini BI, Shah NJ. Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC). JOURNAL OF CLINICAL ONCOLOGY. 2023.